THE CLINICAL DEVELOPMENT OF A 5-ALPHA-REDUCTASE INHIBITOR, FINASTERIDE
THE CLINICAL DEVELOPMENT OF A 5-ALPHA-REDUCTASE INHIBITOR, FINASTERIDE
复制标题
DOI：
10.1016/0960-0760(90)90487-6
复制
发表时间：
1990-11-20
影响因子：
4.1
通讯作者：
STONER, E
中科院分区：
文献类型：
--
作者：
STONER, E
芬达是一种4-氮杂类固醇化合物，是一种口服活性的5-α-还原酶抑制剂。 5-α-还原酶是睾酮（T）代谢为双氢睾酮（DHT）所必需的，仅在某些组织如前列腺中发现高水平。 已显示芬那肽显著抑制人血清DHT水平，而不降低睾酮水平。 在患有良性前列腺增生（BPH）的患者中，发现芬鲁胺在6个月内平均减少前列腺体积28%，而不会引起临床显著的不良反应。 双氢睾酮似乎是前列腺生长的主要雄激素。 非那肽对5-α-还原酶的选择性抑制可能为BPH治疗提供一种新的方法，通过减少前列腺大小而不影响T依赖性过程，如生育力，肌肉力量和性欲。 综述了近年来非那肽治疗前列腺增生症的临床进展。
Finasteride, a 4-aza steroid compound, is an orally active inhibitor of the 5-alpha-reductase enzyme. 5-alpha-Reductase is necessary for the metabolism of testosterone (T) to dihydrotestosterone (DHT) and is found in high levels only in certain tissues such as the prostate. Finasteride has been shown to markedly suppress serum DHT levels in man without lowering testosterone levels. In patients with benign prostate hyperplasia (BPH), finasteride was found to decrease prostate volume by a mean of 28% over a period of 6 months, without causing clinically significant adverse effects. DHT appears to be the primary androgen for prostatic growth. Selective inhibition of 5-alpha-reductase by finasteride may provide a novel approach to BPH therapy by reducing prostate size without affecting T-dependent processes such as fertility, muscle strength, and libido. The clinical development of finasteride for the treatment of benign prostate hyperplasia is reviewed.